Vous êtes un professionnel de la santé et vous avez des questions ou des commentaires sur nos produits?

Soumettre une
question d’ordre
médical

Déclarer une
effet
indésirable

Déposer une
plainte liée à un
produit

Soumettre des
commentaires
généraux

Soumettre une
question
de stabilité

Soumettre une question d’ordre médical

Déclarer une effet indésirable

Déposer une plainte liée à un produit

Soumettre des commentaires généraux

Soumettre une question de stabilité

AlloMerck.ca peut vous aider à trouver ce que vous cherchez.

Visitez AlloMerck.ca

Merck Canada est fière de se joindre à Médicaments novateurs Canada et à d'autres sociétés pharmaceutiques pour aider les travailleurs de la santé de première ligne à lutter contre la COVID-19.

Déclaration de Merck Canada concernant COVID-19

Redéfinir le traitement du cancer met en lumière les immunothérapies du cancer

Santé Canada approuve KEYTRUDA®️ (pembrolizumab) comme traitement de première intention pour les patients atteints d’un adénocarcinome rénal (AR) à un stade avancé

Merck Biosimilaires
est avec vous à chaque étape

Pour en savoir plus

Nous inventons depuis toujours et nous ne cesserons jamais de le faire. Nos efforts ne visent qu’un seul et unique but, le plus important, assurer la vie.

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.